VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results

Viking Therapeutics (VKTX) experienced a significant stock surge, with shares skyrocketing by 35.7%. This market reaction follows the company's announcement of positive results from its GLP-1 weight loss drug trial. Investors are reacting to the successful trial outcomes, which have positioned the company's pharmaceutical development as a key selling point. The positive data from the clinical study has directly driven the rapid increase in the valuation of VKTX stock within the healthcare sector.